Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q2

4574.TEDINET S100RMXK
Period2023-01-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥2.5bn2023-01-01 → 2023-06-30Cons.Net sales
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥1.9bn2022-01-01 → 2022-06-30Cons.Net sales
Operating income−¥396m2023-01-01 → 2023-06-30Cons.Operating income
Operating income−¥2.4bn2022-01-01 → 2022-06-30Cons.Operating income
Ordinary income−¥510m2023-01-01 → 2023-06-30Cons.Ordinary income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.5bn2022-01-01 → 2022-06-30Cons.Ordinary income
Profit before tax−¥492m2023-01-01 → 2023-06-30Cons.Income before income taxes
Profit before tax−¥2.8bn2022-01-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)−¥514m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income−¥514m2023-01-01 → 2023-06-30Cons.Profit loss
Net income−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss
Total assets¥15.6bnat 2023-06-30Cons.Assets
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥17.4bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥6.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Net assets / equity¥9.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥10.2bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥4.8bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
Cash & equivalents¥4.5bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.8bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.4bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.5bnat 2021-12-31dCons.Cash and cash equivalents
Operating cash flow¥126m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥2.0bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥631m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Investing cash flow¥707m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Investing cash flow¥190m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥96m2022-01-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥827m2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥997m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥501m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-11.362023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.762023-04-01 → 2023-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-64.172022-01-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.052022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio58.7%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Otherother segmentsrevenue2023-01-01 → 2023-06-30¥2m
Otherother segmentsrevenue external2023-01-01 → 2023-06-30¥2m
Otherother segmentssegment profit2023-01-01 → 2023-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥492m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥407m
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥514m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-06-30¥95m
Otherother segmentsrevenue2022-01-01 → 2022-06-30¥4m
Otherother segmentsrevenue external2022-01-01 → 2022-06-30¥4m
Otherother segmentssegment profit2022-01-01 → 2022-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-06-30−¥645m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.6bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥117m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-06-30−¥1.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Restoration contribution income noiPrior1YTDDuration－JPY
Restoration contribution income noiCurrentYTDDuration9000000JPY
Other noiPrior1YTDDuration9000000JPY
Other noiCurrentYTDDuration3000000JPY
Non operating incomePrior1YTDDuration72000000JPY
Non operating incomeCurrentYTDDuration51000000JPY
Interest expenses noePrior1YTDDuration5000000JPY
Interest expenses noeCurrentYTDDuration4000000JPY
Plant shutsdown related costs noePrior1YTDDuration154000000JPY
Plant shutsdown related costs noeCurrentYTDDuration145000000JPY
Other noePrior1YTDDuration10000000JPY
Other noeCurrentYTDDuration16000000JPY
Non operating expensesPrior1YTDDuration170000000JPY
Non operating expensesCurrentYTDDuration165000000JPY
Ordinary incomePrior1YTDDuration-2515000000JPY
Ordinary incomeCurrentYTDDuration-510000000JPY
Gain on sales of investment securities eiPrior1YTDDuration－JPY
Gain on sales of investment securities eiCurrentYTDDuration87000000JPY
Extraordinary incomePrior1YTDDuration－JPY
Extraordinary incomeCurrentYTDDuration87000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration3000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration－JPY
Premium allowance of retirement elPrior1YTDDuration226000000JPY
Premium allowance of retirement elCurrentYTDDuration－JPY
Impairment loss elPrior1YTDDuration48000000JPY
Impairment loss elCurrentYTDDuration69000000JPY
Extraordinary lossPrior1YTDDuration277000000JPY
Extraordinary lossCurrentYTDDuration69000000JPY
Income before income taxesPrior1YTDDuration-2793000000JPY
Income before income taxesCurrentYTDDuration-492000000JPY
Income taxes currentPrior1YTDDuration5000000JPY
Income taxes currentCurrentYTDDuration7000000JPY
Income taxes deferredPrior1YTDDuration-0JPY
Income taxes deferredCurrentYTDDuration14000000JPY
Income taxesPrior1YTDDuration4000000JPY
Income taxesCurrentYTDDuration22000000JPY
Profit lossPrior1YTDDuration-2798000000JPY
Profit lossCurrentYTDDuration-514000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-2798000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-514000000JPY
Profit lossPrior1YTDDuration-2798000000JPY
Profit lossCurrentYTDDuration-514000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration－JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration119000000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration139000000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration60000000JPY
Other comprehensive incomePrior1YTDDuration139000000JPY
Other comprehensive incomeCurrentYTDDuration180000000JPY
Comprehensive incomePrior1YTDDuration-2658000000JPY
Comprehensive incomeCurrentYTDDuration-334000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass